
Facilitating Access to Treatment as Prevention

James F Rooney, MD
Gilead Sciences

IAPAC London
June 11, 2012

Facilitating Access to TasP

- ◆ Support HIV testing programs
 - HIV FOCUS program in the US
 - Support testing summits (and TasP meetings) in North America and the EU
- ◆ Facilitate Access to ARVs
 - Patient Assistance Program in the US
 - Gilead Access Program in the developing world
- ◆ Development of new treatment options
 - Effective, well tolerated, simple to administer
 - New single tablet once daily regimens
 - COMPLERA (TDF/FTC/RPV)- Gilead / Janssen
 - QUAD (TDF/FTC/Cobi/EVG)- Gilead
 - FTC/7340/Cobi/DRV- Gilead / Janssen

Gilead Access Program Model

International Access Operations

```
graph TD; A[International Access Operations] --> B[Gilead Brand]; A --> C[Indian Generic Licenses];
```

Gilead Brand

- Access to Viread and Truvada
- 130 countries via distributors
- Tiered Pricing

Indian Generic Licenses

- Provide for adequate capacity in least developed countries
- Proven track record in delivering high volume/low margin quality products
- Achieve the lowest price

Gilead's Indian Generics Partnerships 2006 Agreement


- Gilead has entered into licensing agreements with 13 Indian companies to manufacture API and finished tablets
 - Full technology transfer to enable faster production and ensure quality
 - Develop any tenofovir-based FDC or pediatric formulation
 - Free to sell API within India with no royalty payment to Gilead
 - Free to set own price for finished product, distribute in 95 least developed countries (India, South Africa, Thailand)
 - 5% royalty to Gilead on price of finished goods
 - Seek WHO or tentative FDA approval




International Access Operations Dashboard

Q4 2011

Patients



Price



Registrations

